Profusa, Inc. Common Stock Cash Flow Conversion Efficiency
Profusa, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Profusa, Inc. Common Stock (PFSA) has a cash flow conversion efficiency ratio of 0.091x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.58 Million) by net assets ($-28.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Profusa, Inc. Common Stock (2021–2025)
Cash flow conversion efficiency of Profusa, Inc. Common Stock from 2021 to 2025. This chart illustrates how Profusa, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Profusa, Inc. Common Stock for real-time trading data and today's change.
Profusa, Inc. Common Stock Cash Flow Conversion Ratio Explained
Profusa, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Profusa, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Profusa, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see PFSA stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Medivie Therapeutic Ltd
TA:MDVI
|
0.217x |
|
ALBERT LABS INTL. CORP.
F:VB50
|
N/A |
|
PROPHECY DEFI INC.
F:V8M
|
N/A |
|
GeoVax Labs Inc
NASDAQ:GOVX
|
-1.266x |
|
LIVE MOTION GAMES ZY -10
F:4YM
|
0.873x |
|
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
|
3.264x |
|
Yuilrobotics Co. Ltd.
KQ:388720
|
-0.010x |
|
Carclo plc
LSE:CAR
|
-0.432x |
Annual Cash Flow Conversion Efficiency for Profusa, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Profusa, Inc. Common Stock from 2021 to 2025. Review PFSA free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-26.66 Million | $-16.25 Million | 0.609x | +3416.71% |
| 2024-12-31 | $-119.20 Million | $-2.07 Million | 0.017x | -56.69% |
| 2023-12-31 | $-110.00 Million | $-4.40 Million | 0.040x | -48.16% |
| 2022-12-31 | $-99.77 Million | $-7.70 Million | 0.077x | -39.59% |
| 2021-12-31 | $-83.66 Million | $-10.69 Million | 0.128x | -- |
About Profusa, Inc. Common Stock
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platf… Read more